RESUMO
OBJECTIVE: The objectives of this work were to know the prevalence of methicillin-resistant S. aureus (MRSA) infections in the paediatric population of our health department, to describe the risk factors for infection by MRSA compared to those produced by methicillin-susceptible S. aureus (MSSA) and to know the antibiotic sensitivity profile of MRSA and MSSA isolates. METHODS: A retrospective, descriptive and analytical study of infections produced by MRSA versus those produced by MSSA was carried out during the years 2014 to 2018. Risk factors for MRSA infection were studied using a binary logistic regression model. RESULTS: 162 patients with S. aureus infections were identified. Of these, 25 (15.4%) were MRSA. The highest percentages of MRSA infection occurred among children who required hospital admission (23.4%). In the univariate analysis the need of hospital admission, antibiotic treatment in the last 3 months, the kind of infection and past MRSA infection or colonisation reached statistical significance. However, only the need of hospital admission and antibiotic treatment in the last 3 months maintained statistical significance in the binary logistic regression model. Correct antibiotic treatment was only prescribed in 26.7% of the MRSA infection cases admitted to the hospital. CONCLUSIONS: Our results suggest the need to review empirical local treatment regimen using drugs active against MRSA in infections of probable staphylococcal origin admitted to the hospital, especially if they have received antibiotic treatment in the last 3 months.
Assuntos
Staphylococcus aureus Resistente à Meticilina , Infecções Estafilocócicas , Criança , Humanos , Staphylococcus aureus , Estudos Retrospectivos , Prevalência , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/epidemiologia , Meticilina/uso terapêutico , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Fatores de RiscoRESUMO
La eritrodisestesia palmoplantar es una reacción adversa que se asocia a la administración de docetaxel y fluoropirimidinas. La actividad de la enzima dihidropirimidina deshidrogenasa (DPD) determina la tasa de catabolismo del 5-Fluorouracilo (5-FU) y está sujeta a variabilidad interindividual y polimorfismo genético. Por tanto, los pacientes con deficiencia de DPD presentan un mayor riesgo de toxicidad. Presentamos el caso de un paciente tratado con docetaxel, oxaliplatino y 5-FU (esquema FLOT) que presentó toxicidad cutánea moderada y del que se sospechó deficiencia de DPD.(AU)
Palmoplantar erythrodysesthesia is an adverse event associated with the administration of docetaxel and fluoropyrimidines. The activity of the enzyme dihydropyrimidine dehydrogenase (DPD) determines the rate of catabolism of 5-Fluorouracil (5-FU) and is subject to interindividual variability and genetic polymorphism. Therefore, patients with DPD deficiency present an increased risk of toxicity. We present the case of a patient treated with docetaxel, oxaliplatin and 5-FU (FLOT scheme) who presented moderate skin toxicity and who was suspected of DPD deficiency.(AU)
Assuntos
Humanos , Masculino , Docetaxel , Fluoruracila , Hipestesia , Dor , Pacientes Internados , Exame FísicoRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en agosto, octubre y noviembre de 2019, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in August, October and November of 2019, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the producto
Assuntos
Humanos , Avaliação de Medicamentos , Prova Pericial , Órgãos GovernamentaisRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento publicados en marzo y abril de 2018, considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2018, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Avaliação de Medicamentos/métodos , Equipamentos e Provisões/normas , Avaliação de Medicamentos/normas , Arginina/uso terapêutico , Buprenorfina/uso terapêutico , Antígenos CD34 , Cicloexanos , Lamivudina , Hidroxiureia , Toxinas Botulínicas Tipo A , 58011RESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en diciembre de 2018, enero y febrero de 2019, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in December 2018, January and February of 2019 , and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Avaliação de Medicamentos/métodos , Aprovação de Drogas/métodos , Avaliação de Medicamentos/instrumentação , AnalgésicosRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por la comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en septiembre, octubre y noviembre de 2018. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2018, and considered of interest to the healthcare profesional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Criança , Adolescente , Adulto Jovem , Adulto , Avaliação de Medicamentos/métodos , Avaliação de Medicamentos/normas , Antígenos de Superfície/análise , Vírus da Influenza A/efeitos dos fármacos , Vírus da Influenza B/efeitos dos fármacos , Avaliação de Medicamentos/legislação & jurisprudênciaRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en diciembre de 2017, enero y febrero de 2018, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in December of 2017, January and February of 2018, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Denominação Comercial do Medicamento , Aprovação de Drogas , Preparações Farmacêuticas/administração & dosagem , Comissão para Avaliação de Medicamentos , Espanha , Comercialização de ProdutosRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en marzo, abril y mayo 2017, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Aprovação de Drogas/estatística & dados numéricos , Avaliação de Medicamentos/tendências , Drogas em Investigação , Ensaios de Uso Compassivo , Terapia Biológica/estatística & dados numéricos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologiaRESUMO
La terapia con péptidos análogos de la somatostatina marcados con radionúclidos es un nuevo tratamiento prometedor para tratar tumores neuroendocrinos. El objetivo del presente estudio preliminar es presentar nuestra experiencia en la terapia con 177Lu-DOTATATE y evaluar la tolerabilidad y la eficacia a corto plazo en pacientes con tumores que expresan receptores para la somatostatina. Se han tratado 7 pacientes con tumores neuroendocrinos metastásicos, cada uno con 4 dosis de 177Lu-DOTATATE y se ha evaluado su respuesta al tratamiento en forma de respuesta bioquímica (marcadores tumorales y analítica), según métodos de imagen (gammagrafía de receptores de somatostatina, tomografía computarizada y resonancia magnética) y respuesta funcional y de calidad de vida (mediante la Escala de actividad de Karnofsky). Se ha evaluado también la toxicidad del tratamiento. Los resultados obtenidos han sido los siguientes: respuesta bioquímica: el 60% de los pacientes mostraron una normalización de sus niveles de marcadores tumorales, mientras que en el 40% disminuyeron de manera significativa; respuesta en técnicas de imagen: el 85,7% presentaron una respuesta parcial, mientras que el 14,3% mostraron enfermedad estable; mejoría de la calidad de vida: el 100% de los pacientes mostraron una mejoría significativa en la calidad de vida con un incremento de la Escala de actividad de Karnofsky, y en cuanto a la toxicidad: ningún paciente presentó toxicidad aguda o crónica, y el 42,8% de los pacientes presentaron toxicidad subaguda hematológica transitoria. A pesar de tratarse de un estudio preliminar podemos afirmar que el tratamiento con 177Lu-DOTATATE es un tratamiento seguro, con pocos efectos adversos y que consigue una respuesta objetiva en la mayoría de los pacientes (AU)
Therapy with radiolabelled somatostatin analogue peptides is a promising new therapy to treat neuroendocrine tumours. The aim of this preliminary study is to present our experience with 177Lu-DOTATATE therapy, and evaluate tolerability and short-term efficacy in patients with tumours expressing somatostatin receptors. A total of 7 patients with metastatic neuroendocrine tumours were treated, each with 4 doses of 177Lu-DOTATATE. The treatment response was evaluated in the form of biochemical response (tumour markers), imaging methods (somatostatin receptor scintigraphy, computed tomography, and magnetic resonance), and functional and quality of life responses using the Karnofsky performance status scale. Treatment toxicity was also evaluated. The results obtained were as follows: Biochemical response: 60% of patients showed tumour marker levels returning to normal, while they decreased significantly in the remaining 40%. Imaging response: 85.7% had a partial response, while 14.3% showed stable disease. All (100%) patients showed a significant improvement in quality of life, with increased Karnofsky scale scores. No patient had acute or chronic toxicity, and subacute transient haematological toxicity was observed in 42.8% of patients. Despite being a preliminary study, it was found that treatment with 177Lu-DOTATATE is a safe treatment with few side effects, and an objective response was achieved in most patients (AU)
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Tumores Neuroendócrinos/radioterapia , Tumores Neuroendócrinos , Somatostatina/análogos & derivados , Radioisótopos/uso terapêutico , Qualidade de Vida , Compostos Radiofarmacêuticos/análise , Fluordesoxiglucose F18/administração & dosagem , Cintilografia/métodos , Imageamento por Ressonância Magnética/métodos , Espectroscopia de Ressonância Magnética/métodos , Medicina Nuclear/métodos , Avaliação de Estado de Karnofsky/normas , Tomografia por Emissão de Pósitrons/métodosRESUMO
Therapy with radiolabelled somatostatin analogue peptides is a promising new therapy to treat neuroendocrine tumours. The aim of this preliminary study is to present our experience with 177Lu-DOTATATE therapy, and evaluate tolerability and short-term efficacy in patients with tumours expressing somatostatin receptors. A total of 7 patients with metastatic neuroendocrine tumours were treated, each with 4 doses of 177Lu-DOTATATE. The treatment response was evaluated in the form of biochemical response (tumour markers), imaging methods (somatostatin receptor scintigraphy, computed tomography, and magnetic resonance), and functional and quality of life responses using the Karnofsky performance status scale. Treatment toxicity was also evaluated. The results obtained were as follows: Biochemical response: 60% of patients showed tumour marker levels returning to normal, while they decreased significantly in the remaining 40%. Imaging response: 85.7% had a partial response, while 14.3% showed stable disease. All (100%) patients showed a significant improvement in quality of life, with increased Karnofsky scale scores. No patient had acute or chronic toxicity, and subacute transient haematological toxicity was observed in 42.8% of patients. Despite being a preliminary study, it was found that treatment with 177Lu-DOTATATE is a safe treatment with few side effects, and an objective response was achieved in most patients.
Assuntos
Lutécio/uso terapêutico , Tumores Neuroendócrinos/radioterapia , Octreotida/análogos & derivados , Compostos Organometálicos/uso terapêutico , Radioisótopos/uso terapêutico , Compostos Radiofarmacêuticos/uso terapêutico , Adulto , Idoso , Biomarcadores Tumorais/análise , Feminino , Humanos , Avaliação de Estado de Karnofsky , Lutécio/efeitos adversos , Lutécio/farmacocinética , Masculino , Pessoa de Meia-Idade , Proteínas de Neoplasias/análise , Tumores Neuroendócrinos/secundário , Octreotida/efeitos adversos , Octreotida/farmacocinética , Octreotida/uso terapêutico , Compostos Organometálicos/efeitos adversos , Compostos Organometálicos/farmacocinética , Qualidade de Vida , Radioisótopos/efeitos adversos , Radioisótopos/farmacocinética , Cintilografia/métodos , Compostos Radiofarmacêuticos/efeitos adversos , Compostos Radiofarmacêuticos/farmacocinética , Receptores de Somatostatina/análise , Distribuição Tecidual , Resultado do Tratamento , Imagem Corporal Total/métodos , Adulto JovemRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por la comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en marzo, abril y mayo de 2016. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2016, and considered of interest to the healthcare profesional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Avaliação de Medicamentos , Aprovação de Drogas , Drogas em Investigação/farmacocinética , Vacinas contra Influenza , Ceftazidima , Rilpivirina , TenofovirRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por la comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en junio y julio de 2015. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in june and july of 2015, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Feminino , Humanos , Masculino , Avaliação de Medicamentos/legislação & jurisprudência , Avaliação de Medicamentos/métodos , Avaliação de Medicamentos/normas , Adjuvantes Farmacêuticos/economia , Adjuvantes Farmacêuticos/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Hepatite B/tratamento farmacológico , Hepatite B/imunologia , Avaliação de Medicamentos/economia , Avaliação de Medicamentos/tendências , Avaliação de Medicamentos , Adjuvantes Farmacêuticos/normas , Resultado do Tratamento , Plasmodium falciparumRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hecho públicos en septiembre, octubre y noviembre de 2014, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2014, and considered of interest to the healthcare profesional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Masculino , Feminino , Avaliação de Medicamentos/legislação & jurisprudência , Avaliação de Medicamentos/métodos , Avaliação de Medicamentos , Dermatite Fototóxica/epidemiologia , Dermatite Fototóxica/prevenção & controle , Avaliação de Medicamentos/instrumentação , Avaliação de Medicamentos/tendências , Avaliação de Eficácia-Efetividade de Intervenções , Terapia Combinada/instrumentação , Terapia Combinada/métodosRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios, considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in , and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Aprovação de Drogas , Avaliação de Medicamentos , Aplicação de Novas Drogas em Teste , Serviço de Farmácia HospitalarRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en los meses de junio y julio de 2013, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in June and July of 2013, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Aprovação de Drogas , Medicamentos de Referência , Assistência FarmacêuticaRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el segundo trimestre de 2013, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
Medications are reviewed and evaluated by the Spanish Agency of Medicines and Health Products made public in the second quarter of 2013, and considered of greatest interest to the clinician. It is positive technical opinions that are pre-authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação , Avaliação de Medicamentos , Hormônio do Crescimento Humano , Fator VIII , Condrócitos , DextrometorfanoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el último trimestre de 2012, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the last quarter of 2012, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Medicamentos de Referência , Drogas em InvestigaçãoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el 1er trimestre de 2012, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the first trimester of 2012, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação/análise , Granisetron/uso terapêutico , Agonistas do Receptor de Serotonina/análise , Vacinas Meningocócicas/uso terapêutico , Somatostatina/uso terapêutico , Antraciclinas/uso terapêuticoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el tercer trimestre de 2011, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the third quarter of 2011, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação , Antivirais/farmacologia , Antibacterianos/farmacologia , Hipoglicemiantes/farmacologia , Inibidores da Transcriptase Reversa/farmacologia , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Antagonistas de Androgênios/farmacologiaRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el primer trimestre de 2011, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the first quarter of 2011, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
